What’s newsworthy in the Trenton, N.J., and surrounding areas.
EWING, N.J. — (BUSINESS WIRE) — Cenlar FSB, the nation’s leading mortgage loan subservicer, announced Monday the promotion of Tom Donatacci to Senior Vice President, Chief Client Officer, overseeing Business Development and Client Management. A recognized and highly accomplished leader in the
Patients experienced a 38% reduction in the risk of disease progression or death when treated with Opdivo plus Yervoy versus Opdivo monotherapy across all lines of therapy at median 47 months of follow-up Late-breaking data presented in oral session at the 2025
Hezi Saar of Synopsys appointed board chair; new vice chair and treasurer named for global organization developing interface specifications for mobile, IoT, automotive and related industries BRIDGEWATER, N.J. — (BUSINESS WIRE) — #IoT — The MIPI Alliance, an international organization
Components will be the first-in-human use of OSTAGUARD™ PRINCETON, N.J. — (BUSINESS WIRE) — Orthobond Corporation, a leader in covalently-bound antibacterial surface technologies with broad applications in the medical device industry, today announced the successful in-house production and commercial delivery
PRINCETON, N.J. — (BUSINESS WIRE) — #AAC — Lingraphica, a leader in augmentative and alternative communication (AAC) devices, announced a significant leadership transition. Current Chief Operating Officer Kevin Self has assumed the role of Chief Executive Officer effective Jan. 1, 2025. He
PRINCETON, N.J. — (BUSINESS WIRE) — Essential Properties Realty Trust, Inc. (NYSE: EPRT; “Essential Properties” or the “Company”) announced today that the Company will release its operating results for the fourth quarter ended Dec. 31, 2024, after the market close on Wednesday,
The latest win on the platform adds to the excitement as customers continue to use Jackpot.com to try their luck at Friday’s $1.15 billion Mega Millions jackpot drawing TRENTON, N.J. — (BUSINESS WIRE) — Jackpot.com, the online website and
Opdivo Qvantig is the first and only subcutaneously administered PD-1 inhibitor1 Given over three- to five-minutes, Opdivo Qvantig demonstrated consistent efficacy and showed a comparable safety profile tointravenous Opdivo in the Phase 3 CheckMate-67T trial1,3 PRINCETON, N.J. — (BUSINESS WIRE)
Transaction expected to close in the coming days SOMERSET, N.J. & COPENHAGEN, Denmark — (BUSINESS WIRE) — Catalent, Inc. (“Catalent,” NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (“Novo